The objective of the "Translational excellence in Regenerative Medicine" consortium is to translate national breakthrough proof-of-concept technology in the musculoskeletal and cardiovascular field into clinical trials, paving the way for the development of innovative products.
A unique cooperation between basic scientists from 2 universities, clinical researchers and surgeons from 6 University Medical Centers, and business entrepreneurs from 5 companies, creates an optimal environment for Regenerative Medicine research, development and clinical translation.
Regenerative Medicine (RM) aims to rebuild original tissue function by triggering the intrinsic self-healing capacity of natural tissues. RM replaces conventional medical approaches which treat tissue-related conditions (e.g. traumatized cartilage, malfunctioning heart valves) through removal of damaged tissue or by replacing it through transplantation or implantation.
